Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma

Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.

Abstract

The goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event-free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high-risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early-stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.

Trial registration: ClinicalTrials.gov NCT00302003 NCT00025259 NCT01026220 NCT00107198 NCT00433459 NCT02166463 NCT03407144 NCT03907488 NCT01920932 NCT05705531 NCT05675410 NCT01896999.

Keywords: AYA; Hodgkin lymphoma; pediatric.

MeSH terms

  • Brentuximab Vedotin / therapeutic use
  • Child
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / pathology
  • Humans
  • Immunoconjugates*
  • Neoplasm Recurrence, Local / drug therapy
  • Nivolumab / therapeutic use
  • Progression-Free Survival

Substances

  • Brentuximab Vedotin
  • Nivolumab
  • Immunoconjugates

Associated data

  • ClinicalTrials.gov/NCT00302003
  • ClinicalTrials.gov/NCT00025259
  • ClinicalTrials.gov/NCT01026220
  • ClinicalTrials.gov/NCT00107198
  • ClinicalTrials.gov/NCT00433459
  • ClinicalTrials.gov/NCT02166463
  • ClinicalTrials.gov/NCT03407144
  • ClinicalTrials.gov/NCT03907488
  • ClinicalTrials.gov/NCT01920932
  • ClinicalTrials.gov/NCT05705531
  • ClinicalTrials.gov/NCT05675410
  • ClinicalTrials.gov/NCT01896999